ABT ABBOTT LABORATORIES
Research report · from SEC EDGAR · close 2026-07-10
$93.93 -0.5%
$163.61B mkt cap
executive summary
ABBOTT LABORATORIES (ABT) is a $163.61B company. Revenue is $44.33B (+5.7% y/y) at a 15% net margin. It is profitable. Our health score is C (64/100). No major red flags on file. Smart money is buying (3 insider, 3 Congress, 1 funds). It funds itself; low dilution risk.
Revenue (FY)
$44.33B
+5.7% y/y
✓ No major red flags from our filing-based checks.
who's buying
Insider buys / sells
3 / 0
Cash & ST investments
$7.29B
Operating cash flow
$9.57B
Dilution shelf
active shelf
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated 2026-07-10 by stocktools.ai.